NCT01594749View on ClinicalTrials.gov

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,015

Participants

Timeline

Start Date

September 24, 2012

Primary Completion Date

November 3, 2014

Study Completion Date

November 3, 2014

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

DRUG

Fosaprepitant dimeglumine

DRUG

Fosaprepitant Placebo

DRUG

Dexamethasone

DRUG

Ondansetron

DRUG

Dexamethasone Placebo

DRUG

Ondansetron Placebo

DRUG

Rescue Therapy

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01594749 - Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) | Biotech Hunter | Biotech Hunter